• Prostate Cancer Choices

    Regular screening facilitates early intervention - and early cures

  • General urology

    Specialised care for diseases of the urinary tract and reproductive organs

  • Men’s Health

    Sophisticated, compassionate care and the most innovative treatments for men


  • The Wesley celebrates Australia’s first centre of excellence in robotic surgery

    A/Prof Gianduzzo, chairman of the urology department of the Wesley Hospital, discusses The Wesley Hospital’s accreditation as Australia’s first internationally recognised Centre of Excellence in Robotic Surgery and the importance of surgeon and experience in achieving excellence in outcomes.

    Read More

  • Should patients choose surgery or a radiotherapy option for prostate cancer?

    Quite rightly, patients will often turn to their GP for advice when making this decision.

    Given that 11-18% of men with prostate cancer demonstrate decisional regret over their treatment choice1 it is vitally important that men take the time they need to make the decision that is correct for them. So how should GPs advise them?

    Read More

  • World-leading prostate surgery experts host Wesley Hospital workshop

    World-renowned prostate cancer specialists hosted a workshop in the latest technology for urologists from around Australia and New Zealand.

    The Robotic Prostatectomy Workshop, hosted by The Wesley Hospital, offered specialists the opportunity to hear about technological advances and points of technique.

    Read More

  • Prostate News

    Urologists welcome Pathologis​ts statement on PSA testing for Prostate Cancer

    Read More

  • Urological Society Position Statement on Focal Therapy for Prostate Cancer

    Prostatic focal therapy is an emerging treatment strategy for men diagnosed with prostate cancer. It works on the assumption that the largest focus of cancer in the prostate (the “index lesion”) is predominantly responsible for the risk of cancer recurrence, and that this lesion can reliably be imaged, biopsied and specifically treated. It also assumes that targeting this lesion for focal treatment may lead to equivalent long term cancer survivals compared with whole gland therapies e.g. surgery or radiotherapy with less side effects, and that if unsuccessful that salvage (or additional) therapies can be introduced safely, without compounding side effects. To date, these assumptions are unproven and as such focal therapy of prostate cancer cannot be considered standard of care.

    Read More

Pages [1] 2 of 2 | Next | Last